Richard Marlink, MD

Senior Advisor, Medical and Scientific Affairs

Dr. Richard Marlink oversees EGPAF’s efforts to expand global HIV/AIDS care and treatment services, including antiretroviral treatment. Currently a professor at the Harvard School of Public Health, Dr. Marlink was part of the team that initially identified HIV-2, the second type of HIV, and he helped coordinate research concerning the clinical and biologic characteristics of both HIV-1 and HIV-2. In addition to a number of Botswana clinical studies in which he participates, Dr. Marlink is the principal investigator of Botswana's first large-scale antiretroviral treatment study.